Abnormalities in the plasminogen activator system have been implicated in the pathogenesis of atherothrombotic disorders. In particular, elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), and tPA/PAI-1 complexes have been found to correlate with increased risk of myocardial infarction (Ml) and/or stroke. Vascular fibrinolytic balance is, to a large part, determined by the competing effects of t-PA and PAI-1, and reflects a complex interplay between genetic and environmental factors. For the last several years, this laboratory has been involved in a series of basic and clinical investigations that have served to define hormonal and metabolic factors that contribute to the molecular regulation of PAI-1 and its role in the arterial thrombosis and arteriosclerosis. Based on observations made in genetically modified mice, it was hypothesized that the endogenous plasminogen activators, t-PA and u-PA, in conjunction with thrombomodulin, serve as the critical endogenous defenders against thrombosis in the coronary circulation. Accordingly, an excess of PAI-1 would be expected to increase the risk of coronary thrombosis, since PAI-1 inhibits all three components of this defensive triad, i.e. t-PA, u-PA, and APC. Indeed, there is substantial experimental and epidemiological evidence that PAI-1 may in fact contribute to the development of ischemic cardiovascular disease. In studies supported by this R01, we have engineered novel lines of transgenic mice that overexpress a stable form of human PAI-1 and reported that these animals develop age-dependent spontaneous macrovascular coronary thrombosis and subendocardial myocardial infarction. The central hypothesis of this proposal is that vascular PAI-1 excess promotes the development of intravascular thrombosis and atherosclerosis. This application is composed of four specific aims designed to advance these investigations and specifically to clarify the prothrombotic mechanism of PAI-1 by characterizing new transgenic lines that express specific structural mutations in critical functional domains of the PAI-1 protein. Additionally, we intend to investigate the impact of hyperlipidemia on PAI-1-induced coronary thrombosis and to investigate the role of recently developed PAI-1 antagonists in experimental models of arterial and venous thrombosis. PAI-1 is the major physiologic inhibitor of t-PA in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI-1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI-1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. It is anticipated that these studies will provide new insights into the mechanisms through which PAI-1 contributes to the development of intravascular thrombosis and vascular pathology and identify new approaches for the treatment of PAI-1-associated vascular disease. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL065192-06
Application #
6930306
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Ganguly, Pankaj
Project Start
2000-08-15
Project End
2009-07-31
Budget Start
2005-08-01
Budget End
2006-07-31
Support Year
6
Fiscal Year
2005
Total Cost
$304,167
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Balagopal, P; George, D; Sweeten, S et al. (2008) Response of fractional synthesis rate (FSR) of fibrinogen, concentration of D-dimer and fibrinolytic balance to physical activity-based intervention in obese children. J Thromb Haemost 6:1296-303
Schoenhard, John A; Muldowney 3rd, James A S; Emens, Jonathan S et al. (2007) Plasminogen activator inhibitor-1 has a circadian rhythm in blind individuals. Thromb Haemost 98:479-81
Eren, M; Gleaves, L A; Atkinson, J B et al. (2007) Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost 5:1500-8
De Taeye, Bart M; Novitskaya, Tatiana; McGuinness, Owen P et al. (2007) Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab 293:E713-25
Muldowney 3rd, James A S; Painter, Corrie A; Sanders-Bush, Elaine et al. (2007) Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb Haemost 97:263-71
Muldowney 3rd, James A S; Stringham, John R; Levy, Shawn E et al. (2007) Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 27:400-6
Devin, Jessica K; Johnson, Joyce E; Eren, Mesut et al. (2007) Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. J Mol Endocrinol 39:9-16
Fujita, Hideo; Kang, Myengmo; Eren, Mesut et al. (2006) Foxc2 is a common mediator of insulin and transforming growth factor beta signaling to regulate plasminogen activator inhibitor type I gene expression. Circ Res 98:626-34
De Taeye, Bart M; Novitskaya, Tatiana; Gleaves, Linda et al. (2006) Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 281:32796-805
Smith, Layton H; Dixon, John D; Stringham, John R et al. (2006) Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 107:132-4

Showing the most recent 10 out of 18 publications